As­traZeneca ex­pects 'mod­est prof­itabil­i­ty' for next round of Covid-19 vac­cine sup­ply deals — and prunes pipeline in Q3 up­date

Hav­ing sent 1.5 bil­lion Covid-19 vac­cines around the world on a not-for-prof­it ba­sis, As­traZeneca says it’s time to move in­to “mod­est prof­itabil­i­ty.”

While the pri­or­i­ty is to de­liv­er all the “pan­dem­ic dos­es” — a to­tal of 3 bil­lion are set to be de­liv­ered by the end of the year — As­traZeneca ex­pects to be tak­ing new or­ders in Q4, lead­ing to a blend in sales.

“Don’t ex­pect mas­sive prof­itabil­i­ty, which is some­times the case for oth­er vac­cine mak­ers,” Ru­ud Dob­ber, head of the bio­phar­ma­ceu­ti­cals busi­ness unit, told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER